Kamada Ltd. (NASDAQ:KMDA) Short Interest Update

Kamada Ltd. (NASDAQ:KMDA) was the recipient of a significant increase in short interest in February. As of February 13th, there was short interest totaling 166,435 shares, an increase of 112.9% from the January 29th total of 78,160 shares. Based on an average daily trading volume, of 69,886 shares, the days-to-cover ratio is presently 2.4 days. Approximately 0.5% of the shares of the stock are short sold. Approximately 0.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 69,886 shares, the days-to-cover ratio is presently 2.4 days.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on KMDA shares. Weiss Ratings reissued a “buy (b-)” rating on shares of Kamada in a report on Thursday, January 22nd. HC Wainwright increased their price target on shares of Kamada from $11.00 to $13.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Benchmark reiterated a “buy” rating on shares of Kamada in a research note on Thursday, January 8th. Finally, Wall Street Zen upgraded shares of Kamada from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 13th. Three research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, Kamada currently has a consensus rating of “Moderate Buy” and an average target price of $14.00.

Institutional Investors Weigh In On Kamada

A number of large investors have recently bought and sold shares of the stock. Essex Investment Management Co. LLC raised its holdings in shares of Kamada by 22.4% in the third quarter. Essex Investment Management Co. LLC now owns 396,434 shares of the biotechnology company’s stock worth $2,751,000 after acquiring an additional 72,602 shares during the last quarter. Acadian Asset Management LLC raised its stake in Kamada by 3.1% in the 2nd quarter. Acadian Asset Management LLC now owns 263,556 shares of the biotechnology company’s stock valued at $2,053,000 after purchasing an additional 7,925 shares during the last quarter. Simplicity Wealth LLC acquired a new position in Kamada in the 3rd quarter valued at about $70,000. Huntleigh Advisors Inc. lifted its holdings in Kamada by 4.3% in the 3rd quarter. Huntleigh Advisors Inc. now owns 141,562 shares of the biotechnology company’s stock valued at $982,000 after purchasing an additional 5,786 shares in the last quarter. Finally, XTX Topco Ltd acquired a new stake in shares of Kamada during the 4th quarter worth about $103,000. Institutional investors and hedge funds own 20.38% of the company’s stock.

Kamada Price Performance

KMDA traded down $0.08 during midday trading on Friday, reaching $8.83. 2,977 shares of the company’s stock were exchanged, compared to its average volume of 78,148. Kamada has a 1-year low of $5.54 and a 1-year high of $9.35. The stock has a market capitalization of $508.04 million, a PE ratio of 24.54, a P/E/G ratio of 0.79 and a beta of 0.94. The business’s 50-day moving average price is $8.05 and its 200 day moving average price is $7.33.

About Kamada

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.